Innate Pharma SA Logo

Innate Pharma SA

Developing first-in-class antibody immunotherapies for cancer via the innate immune system.

IPHA | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
117 AVENUE DE LUMINY, 13009 MARSEILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Innate Pharma SA is a global, clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system to discover and develop first-in-class antibody-based therapeutics. Its product portfolio consists of a pipeline of clinical-stage assets, including proprietary programs like lacutamab and partnered assets such as monalizumab. Innate Pharma advances its pipeline through both independent development and strategic collaborations with major pharmaceutical partners, with the goal of improving clinical outcomes and providing new treatment options for patients with high unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Innate Pharma SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Innate Pharma SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Innate Pharma SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America IMMX
IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea 424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan 4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America IMRN

Talk to a Data Expert

Have a question? We'll get back to you promptly.